Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients;Dosages systématiques des marqueurs tumoraux tels que l'antigène carcino-embryonnaire sérique et l'antigène carbohydrate 15-3 dans le dépistage de métastases symptomatiques chez des patientes atteintes d'un cancer du sein

Eastern Mediterranean Health Journal

Volumn 18, Issue 10, 2012, Pages 1055-1059

  Bahrami, A ^a   Mortazavizadeh, M R ^b   Yazdi, M F ^b   Chamani, M ^c  

^a Borhan Research Institute   (Iran)

^b YAZD UNIVERSITY   (Iran)

^c General Practice   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER; TUMOR MARKER CERB2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 85016893262     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2012.18.10.1055     Document Type: Article

References (26)

1. Carcinoembryonic antigen: its role as a marker in the management of cancer. A National Institutes of Health Consensus Development Conference. Annals of Internal Medicine, 1981, 94:407-409.
2. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detection and Prevention, 1988, 12(1-6):321-355.
3. Lang BA et al. Three-year follow-up of carcinoembryonal antigen levels in the serum of patients with breast cancer. Neoplasma, 1984, 31:79-87.
4. Gaglia P et al. Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis. European Journal of Cancer and Clinical Oncology, 1988, 24:1151-1155.
5. Tormey DC et al. Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Cancer, 1977, 39:2397-2404.
6. Falkson HC et al. Carcinoembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy. Cancer, 1978, 42:1308-1313.
7. Lokich JJ, Zamcheck N, Lowenstein MW. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: a predictor and monitor of response and relapse. Annals of Internal Medicine, 1978, 89:902-906.
8. Mughal AW et al. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. Journal of the American Medical Association, 1983, 249:1881-1886.
9. Safi F et al. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer, 1991, 68:574-582.
10. Fletcher RH. Carcinoembryonic antigen. Annals of Internal Medicine, 1986, 104:66-73.
11. Loprinzi CL et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. Journal of Clinical Oncology, 1986, 4:46-56.
12. Tondini C et al. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Research, 1988, 48:4107-4112.
13. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer, 1989, 64:1674-1681.
14. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer (review). In Vivo, 1993, 7(6B):607-613.
15. Colomer R et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Research and Treatment, 1989, 13:123-133.
16. Crippa F et al. Single determination of CA15-3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. Journal of Nuclear Biology and Medicine, 1992, 36:52-55.
17. Dixon AR et al. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer-a comparison with CA15.3. British Journal of Cancer, 1993, 68:947-949.
18. Dnistrian AM et al. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biology, 1991, 12:82-90.
19. Miserez AR et al. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. European Journal of Cancer, 1991, 27:126-131.
20. Molina R et al. MCA in patients with breast cancer: correlation with CEA and CA15-3. International Journal of Biological Markers, 1990, 5:14-21.
21. Molina R et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Research and Treatment, 1995, 36:41-48.
22. Safi F et al. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. International Journal of Biological Markers, 1989, 4:207-214.
23. Sölétormos G et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Annals of Oncology, 1993, 4:861-869.
24. Bon GG et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clinical Chemistry, 1997, 43:585-593.
25. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. Journal of Clinical Oncology, 1996, 14:2843-2877.
26. American Society of Clinical Oncology. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology, 1997, 15:3288.